Activities of garenoxacin (BMS-284756) and other agents against anaerobic clinical isolates

Antimicrob Agents Chemother. 2003 Mar;47(3):910-6. doi: 10.1128/AAC.47.3.910-916.2003.

Abstract

A total of 590 clinical isolates consisting of 33 species of both gram-positive and gram-negative anaerobes were collected from nine centers in the Chicago area in 1998-1999. The largest number of isolates (330 isolates, 56%) belonged to the Bacteroides group. Isolates were tested by agar dilution against garenoxacin (BMS-284756, T-3811 ME), trovafloxacin, moxifloxacin, clindamycin, imipenem, piperacillin-tazobactam, and cefoxitin. All but one species (2% of Bacteroides vulgatus isolates) were fully susceptible to piperacillin-tazobactam and imipenem. A number of species were resistant to clindamycin. Among the fluoroquinolones, garenoxacin and trovafloxacin had an MIC at which 90% of the isolates tested were inhibited of <4 micro g/ml for all but two species (Fusobacterium mortiferum/varium and Peptostreptococcus anaerobius).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Infective Agents / pharmacology*
  • Bacteria, Anaerobic / drug effects*
  • Bacterial Infections / epidemiology
  • Bacterial Infections / microbiology*
  • Chicago / epidemiology
  • Culture Media
  • Fluoroquinolones*
  • Indoles / pharmacology*
  • Microbial Sensitivity Tests
  • Quinolones / pharmacology*

Substances

  • Anti-Bacterial Agents
  • Anti-Infective Agents
  • Culture Media
  • Fluoroquinolones
  • Indoles
  • Quinolones
  • garenoxacin